Table 3.

Diagnostic value of FR+CTC combined with established tumor biomarkers

	AUC	95% CI	P-value	Sensitivity	Specificity
Lung cancer (n=23) vs noncancer (n=40)
CA125 + CYFRA21-1 + NSE	0.8357	0.7266–0.9448	<0.0001	63.6%	92.3%
FR+CTC + CA125 + CYFRA21-1 + NSE	0.8613	0.7652–0.9574	<0.0001	90.9%	66.7%
All cancers (n=34) vs noncancer (n=40)
CA125 + CYFRA21-1 + NSE	0.7692	0.6558–0.8827	<0.0001	66.7%	82.1%
FR+CTC + CA125 + CYFRA21-1 + NSE	0.8485	0.7583–0.9387	<0.0001	87.9%	71.8%

Notes: CYFRA21-1, CA724, and NSE tests had not performed for the lymphoma patient; thus, this patient was excluded from this analysis.

Abbreviation: FR+CTC, folate receptor-positive circulating tumor cell; AUC, area uner the curve; CI, confidence interval; CA, carbohydrate antigen; CYFRA21-1, cytokeratin 19 fragment antigen; NSE, neuron-specific enolase.